You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1821655 |
---|---|
Category | Antibodies |
Description | PD-1 Antibody |
Species/Host | Human |
Clonality | Monoclonal |
Clone Number | 5C4.B8 (Nivolumab) |
Tested applications | Blocking, FC, IHC, SBR |
Reactivity | Human, Monkey |
Isotype | IgG |
Immunogen | mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein consisting of the extracellular domain of PD-1 (amino acids 1–167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies). |
Concentration | 1 mg/ml |
Conjugation | Unconjugated |
Target | PD-1 |
UniProt ID | Q15116 |
Storage | Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C. |
Buffer/Preservatives | PBS with 0.02% Proclin 300. |
Alternative names | CD279; programmed death-1; programmed death 1 ; PD Read more... |
Note | For research use only |
Application notes | Nivolumab has been shown to bind to PD-1-expressing CHO cells (EC50 ~1.66nM). Nivolumab binds CD4+ T cells (EC50 ~0.64 nM) and stains only memory and effector, and not naiive CD4+ or CD8+ T cells from human peripheral blood by FC. The antibody is able to block the interaction between PD-1 and its ligands PDL-1 and PDL-2 (IC50 ~2.52 nM and ~2.59 nM, respectively - determined by SPR) - these IC50 values are also similar to that measured by FACS to evaluate ligand binding to PD-1 expressed on CHO cells. In an allogenic T-cell/DC MLR, Nivolumab-mediated inhibition of PD-1 results in enhancement of IFNγ release, and also enhances IL-2 secretion (97-139% over an isotype control) in response to the superantigen SEB using human peripheral blood mononuclear cells. The same is also observed in a CMV-restimulation assay. Nivolumab at very low concentrations (∼1.5 ng/mL) is able to enhance T-cell reactivity in the presence of a T-cell receptor stimulus - nivolumab has no stimulatory effect in the absence of antigen or T-cell receptor stimulus. In the therapeutically used human IgG4 (S228P) format, this antibody is unable to mediate ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity). |
Expiration Date | 12 months from date of receipt. |
ELISA, IF, IHC-P, WB | |
Rat | |
Human, Mouse | |
Rabbit | |
Polyclonal | |
Unconjugated |
ELISA, FACS, IF, IHC-P, WB | |
Human | |
Mouse | |
Monoclonal | |
Unconjugated |
Filter by Rating